Zacks Investment Research downgraded shares of Bio-Path Holdings Inc. (NASDAQ:BPTH) from a hold rating to a sell rating in a research report sent to investors on Tuesday.

According to Zacks, “BIO-PATH is developing leading-edge, patented, liposomal drug delivery systems, with two clinical cancer drug candidates ready for the clinic and a third siRNA cancer drug undergoing final pre-clinical development. Bio-Path’s drug delivery technology distributes nucleic acid drugs systemically, throughout the human body, via simple intravenous infusion. The delivery technology can be applied both to double stranded and single stranded nucleic acid compounds with the potential to revolutionize the treatment of cancer and other diseases where drugable targets of disease are well characterized. “

Other analysts also recently issued reports about the company. Maxim Group set a $2.00 target price on Bio-Path Holdings and gave the company a buy rating in a research note on Saturday. Rodman & Renshaw set a $5.00 target price on Bio-Path Holdings and gave the company a buy rating in a research note on Thursday, August 11th.

Bio-Path Holdings (NASDAQ:BPTH) traded down 5.04% during mid-day trading on Tuesday, reaching $1.32. The company had a trading volume of 71,271 shares. The company’s market capitalization is $126.25 million. Bio-Path Holdings has a one year low of $0.95 and a one year high of $3.19. The stock has a 50 day moving average price of $1.18 and a 200 day moving average price of $1.76.

Bio-Path Holdings (NASDAQ:BPTH) last posted its quarterly earnings data on Thursday, November 10th. The company reported ($0.02) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.02). On average, equities analysts expect that Bio-Path Holdings will post ($0.09) earnings per share for the current fiscal year.

Several hedge funds have recently modified their holdings of BPTH. Nationwide Fund Advisors purchased a new stake in shares of Bio-Path Holdings during the second quarter valued at approximately $104,000. KCG Holdings Inc. increased its position in Bio-Path Holdings by 79.7% in the second quarter. KCG Holdings Inc. now owns 55,118 shares of the company’s stock worth $110,000 after buying an additional 24,450 shares during the period. Rhumbline Advisers increased its position in Bio-Path Holdings by 18.9% in the third quarter. Rhumbline Advisers now owns 83,540 shares of the company’s stock worth $117,000 after buying an additional 13,300 shares during the period. Panagora Asset Management Inc. bought a new position in Bio-Path Holdings during the third quarter worth about $145,000. Finally, WFG Advisors LP bought a new position in Bio-Path Holdings during the second quarter worth about $204,000. Institutional investors own 19.32% of the company’s stock.

About Bio-Path Holdings

Bio-Path Holdings, Inc is a clinical and preclinical stage oncology focused antisense drug development company. The Company utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Its drug delivery and antisense technology, DNAbilize, is a platform that uses P-ethoxy, a deoxyribonucleic acid backbone modification.

5 Day Chart for NASDAQ:BPTH

Receive News & Stock Ratings for Bio-Path Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path Holdings Inc. and related stocks with our FREE daily email newsletter.